Le Doare Kirsty, Barker Charlotte I S, Irwin Adam, Sharland Mike
Paediatric Infectious Diseases Research Group, St George's University of London, Cranmer Terrace, London, SW17 0RE, UK; Wellcome Trust Centre for Global Health Research, Imperial College, Norfolk Place, London, W2 1NY, UK.
Br J Clin Pharmacol. 2015 Mar;79(3):446-55. doi: 10.1111/bcp.12320.
Antibiotics are a critically important part of paediatric medical care in low- and middle-income countries (LMICs), where infectious diseases are the leading cause of child mortality. The World Health Organization estimates that >50% of all medicines are prescribed, dispensed or sold inappropriately and that half of all patients do not take their medicines correctly. Given the rising prevalence of antimicrobial resistance globally, inappropriate antibiotic use is of international concern, and countries struggle to implement basic policies promoting rational antibiotic use. Many barriers to rational paediatric prescribing in LMICs persist. The World Health Organization initiatives, such as 'Make medicines child size', the Model List of Essential Medicines for Children and the Model Formulary for Children, have been significant steps forward. Continued strategies to improve access to appropriate drugs and formulations, in conjunction with improved evidence-based clinical guidelines and dosing recommendations, are essential to the success of such initiatives on both a national and an international level. This paper provides an overview of these issues and considers future developments that may improve LMIC antibiotic prescribing.
在低收入和中等收入国家(LMICs),抗生素是儿科医疗护理的关键组成部分,在这些国家,传染病是儿童死亡的主要原因。世界卫生组织估计,超过50%的药物存在处方、配药或销售不当的情况,并且一半的患者没有正确服药。鉴于全球抗菌药物耐药性的日益普遍,抗生素的不当使用已成为国际关注的问题,各国在努力实施促进合理使用抗生素的基本政策方面面临困难。LMICs在合理开具儿科处方方面仍然存在许多障碍。世界卫生组织的一些举措,如“让药物适合儿童使用”、《儿童基本药物示范清单》和《儿童处方集范本》,都是向前迈出的重要一步。持续采取战略以改善获得适当药物和剂型的机会,同时改进基于证据的临床指南和剂量建议,对于这些举措在国家和国际层面取得成功至关重要。本文概述了这些问题,并探讨了可能改善LMICs抗生素处方的未来发展。